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Abstract
Marked prolongation of the QT interval on the electrocardiogram associated with the polymorphic ventricular tachycardia
Torsades de Pointes is a serious adverse event during treatment with antiarrhythmic drugs and other culprit medications,
and is a common cause for drug relabeling and withdrawal. Although clinical risk factors have been identified, the syndrome
remains unpredictable in an individual patient. Here we used genome-wide association analysis to search for common
predisposing genetic variants. Cases of drug-induced Torsades de Pointes (diTdP), treatment tolerant controls, and general
population controls were ascertained across multiple sites using common definitions, and genotyped on the Illumina 610k
or 1M-Duo BeadChips. Principal Components Analysis was used to select 216 Northwestern European diTdP cases and 771
ancestry-matched controls, including treatment-tolerant and general population subjects. With these sample sizes, there is
80% power to detect a variant at genome-wide significance with minor allele frequency of 10% and conferring an odds ratio
of$2.7. Tests of association were carried out for each single nucleotide polymorphism (SNP) by logistic regression adjusting
for gender and population structure. No SNP reached genome wide-significance; the variant with the lowest P value was
rs2276314, a non-synonymous coding variant in C18orf21 (p = 361027, odds ratio = 2, 95% confidence intervals: 1.5–2.6).
The haplotype formed by rs2276314 and a second SNP, rs767531, was significantly more frequent in controls than cases (p
= 361029). Expanding the number of controls and a gene-based analysis did not yield significant associations. This study
argues that common genomic variants do not contribute importantly to risk for drug-induced Torsades de Pointes across
multiple drugs.
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Introduction
Marked prolongation of the QT interval on the electrocardio-
gram can occur in an unpredictable fashion during treatment with
both QT interval-prolonging antiarrhythmic drugs as well as with
drugs prescribed for non-cardiovascular indications [1,2]. Such
QT interval prolongation, in turn, is associated with a morpho-
logically-distinctive and potentially fatal polymorphic ventricular
tachycardia termed Torsades de Pointes (TdP). This severe
adverse event (SAE), drug-induced Torsades de Pointes (diTdP),
occurs in 1–5% of patients exposed to QT-prolonging antiar-
rhythmics (most often prescribed for atrial fibrillation, AF), and is
much less common in patients treated with ‘‘non-cardiovascular’’
QT culprit drugs. Clinical risk factors have been identified and
these include female gender, hypokalemia, bradycardia, and
recent conversion from AF to normal rhythm. Basic electrophys-
iologic studies have demonstrated that inhibition of a major
repolarizing potassium current, IKr, is the common mechanism
across multiple drugs and drug classes [1–3]. In addition, for
specific drugs, inhibition of metabolism or elimination leading to
accumulation of high drug concentrations in plasma has been
implicated. This SAE has been a leading cause for drug
withdrawal and relabeling, and evaluation of the potential that a
new drug entity will carry a risk of diTdP has become a standard
component of new drug evaluation [4].
A number of lines of evidence suggest that genomic variants
may contribute to variable susceptibility to diTdP. The syndrome
phenocopies many of the clinical features of the congenital long
QT syndrome, a disease caused by mutations in genes encoding
ion channels or their function modifying subunits [3,5], and case
series have identified mutations in these genes in a minority of
patients with diTdP but normal QT intervals at baseline [6–8];
this is thought to represent incomplete penetrance of the
congenital syndrome. Further evidence for a genetic contribution
to diTdP is provided by a report that QT interval responses to
challenge with the antiarrhythmic quinidine were greater among
first-degree relatives of patients with diTdP than among controls
[9]. Finally, the duration of the QT interval itself is known to be
heritable [10-13], and multiple genomic loci have been highly
significantly and reproducibly associated with this variability
[14,15].
The genome-wide-association study (GWAS) paradigm has
previously been used to identify strong signals for susceptibility to
SAEs using small numbers (,100) cases [16–18]. We present here
the results of a GWAS to test hypothesis that common genomic
variation contributes to risk for diTdP. Cases were accrued by two
multicenter collaborations and compared to drug-challenged
controls manifesting no major QT interval prolongation as
defined below and to population controls. In this analysis, we
find no highly statistically significant association between common
single nucleotide polymorphisms and risk for diTdP in a
Northwestern European population.
Methods
Cases
Cases of diTdP reported here were ascertained using the
common definition below by two groups: the Trans-Atlantic
Alliance Against Sudden Death supported by the Fondation
Leducq and the Drug-induced Arrhythmia Risk Evaluation
(DARE) study [5]. The Leducq set was collected by six North
American and European University Medical centers: Vanderbilt,
Miami, Munster, Amsterdam, Nantes, and Munich. The DARE
study is a systematic national study of cases of British drug-induced
arrhythmia identified prospectively over an initial 5 year period
(2003-8).
A common case definition of diTdP was utilized: documented
polymorphic ventricular tachycardia; typical pause-dependent
initiation; association with exposure to a known or likely culprit
drug with resolution of TdP and at least partial resolution of QT
prolongation with removal of drug exposure. QT interval
prolongation was also required; this was most often documented
by a single lead rhythm strip, and was thus not further quantified
in the majority of cases. Cases of diTdP occurring in subjects with
known or later identified congenital long QT syndrome were not
excluded. Those associated with clear acute cardiac ischemia
(which may represent a different mechanism) were excluded.
Structural heart disease was not an exclusion criterion. Age,
gender, culprit drug, presence of atrial fibrillation (AF), and self-
reported ethnicity were collected as covariates.
Controls
There were three control groups: (1) Drug-challenged controls:
a set of 470 subjects ascertained at Vanderbilt who were
challenged with intravenous ibutilide or oral antiarrhythmics
(sotalol, dofetilide, or quinidine) and who did not display any QTc
interval .500 msec or any increase in QT .50 msec; and (2) 649
general population control (POPRES) [19] including Northwest-
ern European subjects and Europeans from other sub-populations.
The primary analysis was subsequently supplemented with a
further 4231 British subjects from the Wellcome Trust Case
Control Consortium phase 2 (WTCCC2), downloaded from
http://www.ebi.ac.uk/ega/page.php. Because diLQTS is rare in
the population, using a large population control set increases
power even recognizing the (small) potential for misclassification
[20]. Population controls have been successfully used in this
fashion in previous studies of rare adverse drug reactions in which
GWAS did yield significant associations [16,21].
Ethics statement
Cases recruited at Vanderbilt Medical Center provided written
informed consent for participation under a protocol entitled
‘‘Screening for Genetic Causes of Cardiac Arrhythmias’’ approved
by the Vanderbilt Human Research Protection Program (date of
latest approval Dec. 11, 2012). All patients give their written
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consent to participate, and the signed consent form is retained in
the patients’ research chart to document the consent process. For
minors, written consent was obtained from parent/guardian. For
minors ages 12 and older, written consent was obtained from the
child also. Under the age of 12, verbal assent was obtained from
the child. The signed consent form is retained in the patients’
research chart to document the consent process.
Drug-exposed controls provided written consent under a
protocol entitled ‘‘Pharmacogenomics of Arrhythmia Therapy-
Ion Channel Variants and QT-Prolonging Antiarrhythmics’’
approved by the Vanderbilt Human Research Protection Program
(date of latest approval Dec. 13, 2012). All patients give their
written consent to participate, and the signed consent form is
retained in the patients’ research chart to document the consent
process. For minors, written consent was obtained from parent/
guardian. For minors ages 12 and older, written consent was
obtained from the child also. Under the age of 12, verbal assent
was obtained from the child. The signed consent form is retained
in the patients’ research chart to document the consent process.
Cases accrued by the Leducq network provided written consent
approved by local ethics boards. These are: at Nantes: CPP and
ministe`re de la recherche: biocollection de l’institut de thorax
intitule´e « Ge´ne´tique et biomarqueurs des pathologies cardiovas-
culaires, respiratoires et leur facteur de risques ». Declared under
the ref nu DC-2011-1399; at Mu¨nster: local ethics committee,
University Hospital Mu¨nster; at Amsterdam: Medisch Ethische
Commissie AMC (Medical Ethical Committee Academic Medical
Centre, University of Amsterdam, Amsterdam); at Munich:
Ethikkommission bei der LMU Mu¨nchen; at Miami: University
of Miami Institutional Review Boards. Consent for inclusion in the
DARE study was given under Multi-Centre Research Ethics
Committee approval MREC 02/02/73 on February 24th 2003
with minor amendment approval given on February 3rd 2010.
Genotyping
The Leducq cases and the drug-exposed controls were
genotyped on the Illumina 610k platform by the RIKEN Center
for Genomic Medicine (Yokohama, Japan) as part of a collabo-
ration between RIKEN and the National Institutes of Health-
supported Pharmacogenetics Research Network. The DARE cases
and the POPRES and WTCCC2 controls were genotyped using
the Illumina 1M or 1M-Duo chip. We used a consistent QC
procedure for each genotyping assay, as previously described
[16,21]: SNPs required a call rate . 0.95, minor allele frequency
. 0.01, and Hardy Weinberg Equilibrium (HWE) in controls
p.1027, and subjects required a call rate . 0.9. We tested for
cryptic relatedness by estimating identity-by-descent (IBD) for all
possible pairs of individuals using PLINK [22].
Principal components analysis (PCA)
We used the smartPCA program from the EIGENSTRAT
package (version 3.0) [23] to conduct a PCA in order to expose
population structure. SNPs from known regions of long-range
linkage disequilibrium [24] were removed before conducting the
PCA. We first analyzed the study genotype data to identify major
ancestry groups (Europeans, Asians and Africans). We then
conducted a PCA on Europeans to separate sub-populations
within this group.
Statistical analyses
We conducted statistical tests using PLINK v1.05 [22]. The
primary analysis compared the cases of Northwestern European
ancestry to genetically matched controls. We conducted analyses
comparing cases to drug-exposed controls, to the POPRES
population controls, to drug-exposed + POPRES controls, and
to drug-exposed + POPRES + WTCCC2 controls. The initial
analysis was conducted on the set of SNPs common across all sets,
and as discussed below, we also extended the analysis to an
imputed set. We also analyzed drug-specific sets for the three most
common culprit agents, sotalol, amiodarone and quinidine, and
searched for associations using gene-specific analyses, as described
further below.
We tested the association of single SNPs with diTdP suscepti-
bility using logistic regression, with gender and Eigen score as
covariates in an additive model. We set the genome-wide
significance threshold of P-value at to 561028 to correct for
multiple testing. The power calculation with Bonferroni correction
was based upon the following assumptions: 265 cases; a low
prevalence of diTdP in the general population; a SNP minor allele
frequency (MAF) of 0.1; a 0.8 R2 coefficient between the SNP and
the causal allele; and an odds ratio (OR) in the range of 1.5 and
2.5. The power was calculated based on a chi-square test under an
additive model, using a non-centrality parameter [25]. This
supported the use of the WTCCC2 controls to achieve increased
power (to 29% for OR = 2.0, to 93% for OR = 2.5, and to 99%
for OR = 2.7), in the subsequently analysis of the selective cohorts
(Figure 1).
We calculated r2 among top associated SNPs located in a 1M bp
interval. In the case of two or more SNPs not correlated with each
other, we conducted a haplotype analysis using PLINK.
Imputation
Imputation of missing genotypes was carried out using
IMPUTE2 (February 2009 version) [26], with data from the
1000 Genomes Project (56 individuals, August 2009 release) and
HapMap III (146 individuals, CEU and TSI) as the reference
panels. All known SNPs with poor quality were removed before
the imputation to avoid false positives. Imputed genotypes with a
posterior probability of greater than 0.9 were retained [26]. To
assess the accuracy of the imputation results, we carried out the
following quality control procedures: (1) we tested the difference of
missingness between cases and controls; (2) we tested for HWE (p-
value ,, 0.05); 3) we manually inspected signal quality for all the
SNPs in the haplotype generating the imputed genotype.
Gene-based approaches
We also performed a gene-based GWAS analysis. In this
analysis we aggregated SNPs by the genes they are near to increase
the signal. This approach is based on the idea that multiple
variants in a single gene will perturb gene function [27]. For each
patient in the cases and the controls, we scored each gene by
counting the number of minor alleles in that gene. These counts
are weighted by the negative log of the frequency that the allele is
observed at in the population. This approach up-weights rare
alleles and down-weights common alleles [27]. We then performed
a univariate logistic regression modeling the cases versus controls
as a function of these gene scores. We performed an F-test to assess
the significance of the fit.
Repository information
Portions of the Leducq dataset approved by local IRBs for central
deposit have been uploaded to dbGaP at http://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id = phs000331.v1.p1.
The DARE dataset is held by the International Serious Adverse
Events Consortium (iSAEC) and is available on application to
the iSAEC data management committee at http://www.
saeconsortium.org/.
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Results
There was a total of 264 cases genotyped, 210 from the Leducq
network and 54 from the DARE study. The clinical features of
these sets are presented in Table 1. They included 185 women
(71%), the age range was 7–91, and the most commonly-
implicated drugs were sotalol, amiodarone and quinidine (Table
2). The majority self-declared European ancestry (98% for the
DARE study and 92% for the Leducq network).
Quality control and population structure
Genotype data from the 264 cases and 1119 drug-exposed and
POPRES controls underwent QC as described above. After
dropping SNPs with genotyping efficiency #95% or MAF #1%,
the final set for initial analysis across all platforms used included
478,055 SNPs. Of the 1383 samples, 46 sample pairs had identity-
by-descent sharing values . 0.2 in the Leducq set, and we
removed the sample from each pair with the lower overall SNP
calling rate. In total, we selected for further analyses 242 cases
from all ethnicities (189 from the Leducq set and 53 from the
DARE set) and 1094 controls (435 drug-exposed control and 659
POPRES controls).
After identifying and removing non-Caucasian subjects by PCA,
we investigated the genetic structure of Caucasian cases and drug-
exposed controls. As shown in Figure 2, most cases and controls
clustered in the Northwestern European cohort. We therefore used
samples with PC1.-0.03 to make up the final sets for the primary
analysis; this included 216 cases, 386 drug-exposed controls, and
385 POPRES controls.
Genome-wide statistical analysis
Using logistic regression with the first three significant principal
components and gender as covariates (Figure 3 and 4), we found
no SNPs with p-values ,1027 in separate analyses of cases versus
drug-exposed controls, cases versus population controls, and cases
versus the combined control set (Table 3). In the combined
analysis (Figures 3 and 4), the SNP with the lowest P value in an
additive model (rs2276314, P= 461027, OR=2, 95% CI 1.5–2.7)
was a non-synonymous coding variant in C18orf21, a gene thought
to be transactivated by Hepatitis B virus. There was no significant
difference in MAF between the treatment-tolerant and general
population groups (Table 4), or between subjects with or without
AF, indicating that the association is not likely to be influenced by
confounding factors. Interestingly, the haplotype AA formed by
rs2276314 and rs767531, a nearby SNP, was significantly more
Figure 1. Plot of power versus odds ratios, using 700 controls (initial analysis) and then .4000 controls.
doi:10.1371/journal.pone.0078511.g001
Table 1. diTdP Genome-Wide Association Study: Demographic and clinical characteristics of the enrolled cases summarized by
cohort.
Cohort
Number of
cases enrolled
Number of North-western
European cases
Age at the onset
(Mean, SD)
Female (% of
total)
Atrial Fibrillation
(Yes, % of total)
% self-defined
Europeans
Leducq 210 163 61.9616.5 71% 49% 92% *
DARE 54 53 66.8615.9 64% 52% 98%
Total 264 216 62.5616.3 70% 50%
*In total, 66% of the Leducq cases self-declared ethnicity, among then 92% (61% of total) are Europeans.
doi:10.1371/journal.pone.0078511.t001
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frequent in controls (79% of controls vs. 65% of cases) with a chi-
square p-value of 1.661029. Rs767531 is an intragenic SNP close
to GALNT1, which is thought to mediate O-linked glycosylation in
the Golgi.
We investigated drug-specific risk alleles by comparing the 771
Northwestern European control subjects with three drug-specific
Northwestern European case groups (Figure 5): sotalol (55 cases),
Table 2. diTdP Northwestern European cohort: causal drugs and demographic and clinical characteristics of the diTdP
Northwestern European cases summarized by drug group.
Drugs # Cases Atrial Fibrillation (Yes, %of total) Age (Mean, SD) % Female
Amiodarone 46 50% 62.5617.1 65%
Quinidine 19 63% 55.6622.3 68%
Sotalol 55 53% 55626.5 75%
Others 141 36% 58.2623.8 72%
Subjects might have experienced diTdP due to more than one causal drug.
doi:10.1371/journal.pone.0078511.t002
Figure 2. Population structure of the Caucasian cases and controls. The red dots represent diTdP cases and blue dots represent controls
(drug-exposed patients and population [POPRES] controls). The plot shows the first and second eigen vectors, which clearly separate the Caucasians
into a Northwestern group (top) and other groups from Southern and Eastern Europe. The dense cluster on the lower left represents the subjects of
Spanish origin from the POPRES collection. The final analysis included subjects with PC1,–0.03.
doi:10.1371/journal.pone.0078511.g002
GWAS in Drug-Induced Torsades
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amiodarone (46 cases), and quinidine (19 cases). We found no SNP
with genome-wide significance in any of the three comparisons.
An initial analysis of the two cohorts separately did suggest
possible signals at or near genome-wide significance, but these
signals were not observed in the combined analysis presented here.
For example, the initial analysis of the DARE set identified
rs2200733 as a potential risk allele. This variant has previously
been associated with AF [28] and thus may represent the fact that
antiarrhythmic drugs, the most common culprit agents for diTdP,
are most often prescribed for patients with AF. The association
was not seen in the Leducq set or in the combined analysis.
Alternate analytic approaches
We used imputation to increase the number of SNPs evaluated
to 3,542,142 as described in the methods section. We repeated the
phenotype and drug specific analyses and we found no genome-
wide significant associations. We also obtained no significant
associations by including the WTCCC2 controls.
Using the gene-based GWAS analysis method described, we did
not find any significant associations at the p,1026. The most
significant association encoded for a cytochrome P450 enzyme,
CYP2U1 on chromosome 4 (p= 1.261025), followed by ubiquitin,
USP25 on chromosome 21 (p= 3.461025), and a G protein-
coupled receptor, OPRL1 on chromosome 20 (p= 9.261025).
As mentioned above, small series have identified occasional
patients with incompletely penetrant congenital long QT syn-
drome that becomes manifest with drug exposure [6–8]. In a
minority of diTdP cases analyzed here (n = 66–132), coding region
resequencing in six congenital long QT syndrome disease genes
had previously been undertaken. As shown in Table 5, this effort
identified 10 rare variants implicated as function-altering likely
congenital syndrome mutations [6,29,30].
Discussion
Severe adverse events during drug therapy are by their nature
unpredictable: if markers of high risk are known, they could be
used to reduce or even eliminate risk in an individual subject or for
a drug or drug class. The very unpredictable nature of many such
events has prompted a search for underlying markers of genomic
susceptibility. In the case of diTdP, a contribution by a genomic
component is especially appealing given the clinical similarity to
the congenital long QT syndrome, evidence that QT interval
responses to drug challenge may be exaggerated among relatives
of those with diTdP, and the known heritability of QT duration.
One of the major impediments to identifying genomic markers
of risk for TdP or other severe adverse drug reaction is the very
rarity of the event that precludes accumulation of large numbers of
cases [31]. This integrated analysis of two large multi-institutional
ascertainment efforts presented here represents the largest such
effort for diTdP to date. The analysis did not identify common
variants conferring high risk for diTdP. This negative finding
suggests that it is unlikely that any single common genomic
Figure 3. QQ plot of the results from logistic regression on the
Northwestern European cohort. The x axis is –log10 of the
expected P-value and the y axis is –log10 of the observed P-values.
Black solid lines denote the null distribution. The bulk of the values (red
dots) closely follow the expectation under the null model (black line)
showing that there is no significant inflation of test statistic due to
factors such as population stratification. The tail end shows significant
deviation from null model illustrating that there are a few observed
significant associations.
doi:10.1371/journal.pone.0078511.g003
Figure 4. Manhattan Plot of logistic regression on Northwestern European cohort. Each dot represents a SNP. The x axis represents the
position of the SNP on chromosome. The y axis represents the -log10 of logistic regression P-value of the SNP in the case-control association study.
rs2276314 and rs4799838 are marked in green with the P-value just below the genome-wide threshold (dashed line).
doi:10.1371/journal.pone.0078511.g004
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markers of risk with odds ratios greater than 2.5 contribute. The
result leaves open the possibility that predisposition to diTdP is
determined by interactions of multiple variants each with modest
effect sizes, or that rare variants play a prominent role. Indeed, a
recent large-scale candidate gene analysis of the Leducq set
implicated an uncommon non-synonymous variant in the
potassium channel subunit KCNE1: minor allele frequency in
control populations was 1.8–2.9% and 8.6% in cases [32]. A trend
in the same direction was seen in the DARE set.
In addition, environmental factors may also be important; these
include electrolyte abnormalities, alterations in autonomic tone or
heart rate, or underlying heart disease. Indeed, the signal observed
in the DARE set between AF risk alleles and diTdP may represent
confounding by indication (i.e. AF is an indication for the culprit
drugs) or may represent an association between homeostatic
perturbations induced by AF and subsequent susceptibility to
diTdP. Studies of QT interval during AF have identified abnormal
control of repolarization (very flat QT-RR relationships; i.e.
absence of expected QT prolongation at slower heart rates) during
the arrhythmia, with normalization or even super-normalization
(i.e. longer than expected QT interval at any given heart rate) after
conversion to normal rhythm [33,34]. The mechanism underlying
these changes has not been elucidated, although it is known that
the neurohormonal milieu does change shortly after conversion to
normal rhythm: for example, catecholamines [35] and atrial
natriuretic peptides [36] are higher during AF than after
conversion. These changes may contribute to altered QT-RR
regulation and susceptibility to diTdP after conversion to normal
rhythm [33].
The SNP with the lowest P value is a non-synonymous variant
in C18orf21 that results in a substitution of an alanine for a
threonine at position 132 of the protein. The threonine is a
predicted phosphorylation site (according to the NetPhos 2.0
website). The function of this transcript is unknown, so this signal
may represent new biology or a false positive.
Limitations
In contrast to the present study, the GWAS paradigm has been
used to identify single loci with strong effects in other adverse drug
reactions. Carbamazepine-related skin toxicity [17] and fluclox-
acillin-related hepatotoxicity [16] were linked to variants in the
HLA locus in studies using discovery sets of 65 and 51 cases
respectively. Similarly, a GWAS of 85 cases of myotoxicity related
to high dose simvastatin identified variants at the SLCO1B1 locus,
encoding a statin drug transporter [18]. The present study also
Table 4. Minor Allele Frequency (MAF) for rs2276314, the top
associated SNP, in different sample sub-groups.
sub-groups MAF
DC controls (382) 0.19
POPRES controls (389) 0.19
subjects with AF (371) 0.23
subjects without AF (182) 0.21
Abbreviations: AF (atrial fibrillation), MAF (minor allele frequency).
doi:10.1371/journal.pone.0078511.t004
Table 5. Screening rare variants in congenital long QT
Syndrome disease genes in 216 diTdP cases.
KCNQ1 KCNH2 SCN5A ANK2 KCNE1 KCNE2
Number
screened
131 132 129 66 89 80
Rare variants
identified
3 3 1 2 1 0
Rare variants
identified
W305X R784W A385T T1404I D76N
T224M G934V V1516D
R954C
doi:10.1371/journal.pone.0078511.t005
Table 3. diTdP Genome-Wide Association Study: top associated SNPs.
SNP CHR Position functional type closest gene OR P-value
rs2276314 18 33557466 Non synonymous C18orf21 2.0 (1.5–2.6) 4.0610207
rs4799838 18 33597530 Intronic variant RPRD1A 1.9 (1.5–2.5) 9.4610207
rs9960370 18 33494636 Intergenic variant MIR187 2.0 (1.4–2.7) 6.0610206
rs767531 18 33357868 Intergenic variant GALNT1 3.0 (1.8–4.8) 7.1610206
rs1789536 18 33524398 Intergenic variant C18orf21 2.0 (1.4–2.7) 7.4610206
rs1789532 18 33532322 Intergenic variant C18orf21 2.0 (1.4–2.6) 7.9610206
rs10141001 14 52132201 Intronic variant FRMD6 2.0 (1.4–2.7) 1.0610205
rs9805984 14 52131743 Intronic variant FRMD6 2.0 (1.5–2.7) 1.0610205
Abbreviations: OR (Odds Ratio, OR is expressed with a confidence interval of 95%), CHR (chromosome).
doi:10.1371/journal.pone.0078511.t003
Figure 5. The effect size (OR) of rs2276314 in different drug-
specific groups. The numbers in parentheses are the numbers of
cases for each group. The horizontal blue lines mark the 95%
confidence interval of odds ratios.
doi:10.1371/journal.pone.0078511.g005
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examined a rare adverse drug reaction and included 216 cases
with a well-defined genetic background, but did not identify loci
strongly associated with diTdP. We believe this indicates that
variants at a single locus do not have a strong influence on diTdP
risk across drugs and drug classes. Basic electrophysiologic studies
have implicated a common mechanism across multiple drugs,
block of the rapid component of the delayed rectifier potassium
current IKr, in diTdP [4,37] and justify the inclusion of multiple
culprit drugs in the present study. This design will not detect drug-
specific mechanisms predisposing to diTdP; examples could
include alterations in elimination pathways or in drug-specific
(e.g. non-IKr-mediated) electrophysiologic pathways leading to
diTdP [38]. The analysis by drug performed here did not yield any
suggestive signals, but the numbers are small; similarly, an analysis
by gender did not yield significant associations. We also did not
exclude patients with heart failure, which is associated with QT
prolongation. A recent study of amiodarone-related diTdP [39],
using the multiple SNPs interrogated by the cardiochip, has
suggested that variants in the NOS1AP locus, known to modulate
baseline QT interval [14,15], also confer risk for amiodarone-
related TdP. Rare variants may contribute to susceptibility,
although screening in congenital long QT syndrome disease genes
yielded likely contributory mutations in 0–3% (depending on the
gene; Table 5) of subjects.
Small numbers of cases represent a generic problem in the study
of rare adverse drug events and support the development of
further multi-institutional efforts to accrue cases and controls
under uniform protocols and definitions [31,40]._ENREF_24 The
present study cannot address whether there are common genomic
variants that confer risk in subjects of non-Northwestern European
ancestry. One small association study has suggested that the
common S1103Y variant in the cardiac sodium channel gene
SCN5A, seen almost exclusively in subjects of African origin,
confers increased risk for a range of arrhythmias, including diTdP
[41]. Follow-up clinical and in vitro studies have further supported
a role for this variant in arrhythmia susceptibility [42,43]. It is
possible that gene-gene interactions drive susceptibility to diTdP
but the present study is not powered to detect such associations.
In conclusion, the results described here represent analysis of
the largest number of genotyped cases of diTdP reported to date,
and effectively rule out any likely role for common variation with
anything other than modest effects. Further efforts to define risk
for the adverse drug event would benefit from accrual of larger
patient sets and extension of analytical approaches to sequence-
based analysis to further explore the hypothesis that rare variants
(e.g. in congenital arrhythmia syndrome genes) mediate diTdP
risk. The precise role of genetic variation in the risk of diTdP
remains to be determined.
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